Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human BRCA2 Antibodies:
anti-Rat (Rattus) BRCA2 Antibodies:
anti-Mouse (Murine) BRCA2 Antibodies:
Go to our pre-filtered search.
Human Monoclonal BRCA2 Primary Antibody for IHC, IHC (p) - ABIN445491
Wu, Jiang, Thangaraju, Wu, Couch: Induction of the BRCA2 promoter by nuclear factor-kappa B. in The Journal of biological chemistry 2000
Show all 2 Pubmed References
Human Monoclonal BRCA2 Primary Antibody for IHC, IHC (fro) - ABIN445493
Bernard-Gallon, Déchelotte, Vissac, Aunoble, Cravello, Malpuech, Bignon: BRCA1 and BRCA2 protein expressions in an ovotestis of a 46, XX true hermaphrodite. in Breast cancer research : BCR 2001
Show all 2 Pubmed References
Human Polyclonal BRCA2 Primary Antibody for ICC, IF - ABIN4285198
Sergeeva, Ershova, Veiko, Malinovskaya, Kalyanov, Kameneva, Stukalov, Dolgikh, Konkova, Ermakov, Veiko, Izhevskaya, Kutsev, Kostyuk: Low-Dose Ionizing Radiation Affects Mesenchymal Stem Cells via Extracellular Oxidized Cell-Free DNA: A Possible Mediator of Bystander Effect and Adaptive Response. in Oxidative medicine and cellular longevity 1970
Evidence has been provided that the majority of the Cas9-induced single nicks at the target DNA strand rely on RAD51 (show RAD51 Antibodies) and BRCA2 for efficient and scar-less DNA repair.
It has been shown that BRCA2-mutant prostate cancer cells harbor increased genomic instability and a mutational profile that more closely resembles metastatic than localized disease.
Both BRCA1 and BRCA2 mutations are associated with an increased risk for Prostate cancer(PC). BRCA2 in particular confers a more aggressive PC phenotype with a higher probability of locally advanced and metastatic disease, and should be considered a prognostic marker associated with poorer survival
Among BRCA mutation( BRCA1 or BRCA2) carriers, the mortality benefit of preventive mastectomy at age 25 is substantial, but the expected benefit declines rapidly with increasing age at surgery.
The present study demonstrates a clear protective effect of early first pregnancy on breast cancer risk in both BRCA1 and BRCA2 mutation carriers.
Overall, 5152 oncogenetic tests were reviewed in the present study, of which 4452 had no a priori known familial mutation. The majority of participants (68.6%) were genotyped because of personal history of cancer; 20.6% were tested because of family history of cancer, and details for the remaining 10.7% were missing. Overall, 256/4452 (5.8%) carriers were detected, 141 BRCA1 and 115 BRCA2 mutation carriers.
The present study aimed to clarify the clinicopathological features, including the level of p53 (show TP53 Antibodies) protein expression and BRCA mutations, of primary fallopian tube cancer (PFTC) in Japanese women.
Germline mutations involving the Fanconi anemia (show PALB2 Antibodies) pathway, such as BRCA2 are often implicated in Invasive Pancreatic Ductal Adenocarcinoma.
Authors found that BRCA1/2 germline mutations in China exhibit distinct characteristics compared to those in Western populations.
We show a strong association between Triple Negative Breast Cancer and mutations in BRCA1/2 genes and the poor outcome of these patients. The survival curve analysis showed that the presence of AKT1 (show AKT1 Antibodies), TP53 (show TP53 Antibodies), KDR (show KDR Antibodies), KIT, BRCA1 and BRCA2 mutations is correlated with a poor prognosis.
persistent meiotic DNA double-strand breaks might correspond to crossovers, which are mobilized to the nuclear envelope for their repair; Brca2-Pds5 complexes may be key mediators of this process.
A mutation in Cyp6d2, a cytochrome P450 (show PHM Antibodies) gene, when combined with a brca2 mutation, resulted in synergistic hypersensitivity to camptothecin.
DNA repair by homologous recombination is dramatically decreased in CG30169 (brca2 homolog) mutants.
the data suggest for the first time that brca2/fancd1 is essential for vertebrate kidney ontogeny.
Carcinogenesis in zebrafish with combined mutations in tp53 (show TP53 Antibodies) and brca2 typically requires biallelic mutation or loss of at least one of these genes.
The novel role of Brca2 in organizing the vertebrate egg nucleus may provide new insights into the origin of ovarian cancer
critical roles for brca2 in ovarian development and tumorigenesis in reproductive tissues
Results suggest that the greater reliance on homology-directed repair (HDR (show GATA3 Antibodies)) in the proliferating mammary gland, rather than a specific dependence on breast cancer 2 protein (BRCA2), may increase its susceptibility to tumorigenesis incurred by BRCA2 mutation.
The functional consequence of Parp1 (show PARP1 Antibodies) heterozygosity on BRCA2 loss is demonstrated by a significant increase in tumorigenesis in Brca2 knockout mice.
Data indicate the importance of breast cancer 1 (show BRCA1 Antibodies) protein (BRCA1 (show BRCA1 Antibodies))/breast cancer 2 protein (BRCA2) function in cranial neural crest cells (CNCCs) during craniofacial skeletal formation.
we generated a Brca2 knock-in mouse model lacking exons 4-7 and demonstrated that these exons are dispensable for viability as well as tumor-free survival. This study provides the first in vivo evidence of the functional significance of a minor transcript of BRCA2 that can play a major role in the survival of humans who are homozygous for a clearly pathogenic mutation.
we describe a genetic approach to examine the functional significance of the interaction between BRCA2 and PALB2 (show PALB2 Antibodies) by generating a knock-in mouse model of Brca2 carrying a single amino acid change (Gly25Arg, Brca2G25R) that disrupts this interaction. In addition, we have combined Brca2G25R homozygosity as well as hemizygosity with Palb2 (show PALB2 Antibodies) and Trp53 (show TP53 Antibodies) heterozygosity .
Merit40 (show BABAM1 Antibodies) mutation exacerbated ICL-induced chromosome instability in the context of concomitant Brca2 deficiency but not in conjunction with Fancd2 (show FANCD2 Antibodies) mutation.
Heterozygous and homozygous Brca2 mutation may lead to dysfunction in T cell populations.
BRCA2 exon 27 domain maintains chromosomal integrity at both stalled and collapsed replication forks consistent with involvement in both replication fork maintenance and double strand break repair.
we use a genetically engineered mouse model of BRCA2-associated hereditary breast cancer to study drug resistance to several types of chemotherapy and PARP (show PARP1 Antibodies) inhibition.
BRCA2-mediated sequestration of nuclear RAD51 (show RAD51 Antibodies) serves to prevent inappropriate DNA interactions.
Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele.
BRCA1/BRCA2-containing complex, subunit 2
, breast and ovarian cancer susceptibility gene, early onset
, breast cancer 2 tumor suppressor
, breast cancer type 2 susceptibility protein
, fanconi anemia group D1 protein
, truncated breast and ovarian cancer susceptibility protein 2
, breast cancer 2, early onset homolog
, breast cancer 2, mutation 1, University of Wisconsin-Madison
, breast cancer susceptibility protein 2
, breast cancer type 2 susceptibility protein homolog
, fanconi anemia group D1 protein homolog
, breast and ovarian cancer susceptibility protein 2
, breast cancer 2, early onset
, breast cancer type 2 susceptibility protein-like